One of the primary factors driving the growth of the market is the rising prevalence of organ failure. In addition, the rising popularity of non-invasive diagnostic methods across the globe is another key driver for market growth. Advancements in organ preservative techniques also influence the market. However, the shortage of professionals with expertise in transplant diagnostics is restraining the market growth.
On the other hand, strategic initiation and technology launches by the market players act as an opportunity for market growth. However, ethical challenges faced during organ transplantation may create a challenge to market growth.
The demand for diagnostic tests will increase due to rising technological advancements. Thus, various companies are taking initiatives that gradually lead to market growth.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-pcr-based-transplant-diagnostics-market
Data Bridge Market Research analyses that the Global PCR Based Transplant Diagnostics Market is expected to reach USD 995,007.52 thousand by 2031, from USD 612,500.00 thousand in 2023, growing with a CAGR of 6.5% in the forecast period of 2024 to 2031. The CMV PCR test segment is projected to propel the market growth and increase applications of global PCR based transplant diagnostics worldwide.
Key Findings of the Study
Strategic Initiation and Technology Launches by Market Players
The escalating growth in the PCR based transplant diagnostics market, driven by the increased demand for donor organs, emphasizes strategic initiatives such as partnerships, business expansions, and developmental endeavors. These initiatives, guided by well-thought-out strategies, include the introduction of transplant diagnostic kits, such as the Aspergillus Spp PCR Test, PCR Test, CMV PCR Test, EBV PCR Test, BKV PCR Test, and VZV PCR Test. Implementing these strategic frameworks enables market participants to harmonize with their organizational activities, enhancing operational efficiency and aligning efforts with the dynamic landscape of transplant diagnostics.
Hence, these strategic initiatives by the market players may be expected to act as an opportunity for market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Test Type (CMV PCR Test, EBV PCR Test, BKV PCR Test, VZV PCR Test, HSV1 PCR Test, HSV2 PCR Test, Parvovirus B19 PCR Test, P. Jirovecii PCR Test, JCV PCR Test, Adenovirus PCR Test, and Aspergillus Spp PCR Test), Transplant Type (Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Pancreas Transplantation, and Other Transplantations), Application (Diagnostic Applications and Research Applications), End User (Hospitals and Transplant Centers, Commercial Service Providers, Research Laboratories, and Academic Institutes)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Quest Diagnostics Incorporated. (U.S.), Laboratory Corporation of America Holdings (U.S.)., EUROFINS VIRACOR (U.S.), Sonic Healthcare Limited (U.S.), and Dr Lal PathLabs (India) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
The global PCR based transplant diagnostics market is segmented into four notable segments based on test type, transplant type, application, and end user.
- On the basis of test type, the global PCR based transplant diagnostics market is segmented into CMV PCR test, EBV PCR test, BKV PCR test, VZV PCR test, HSV1 PCR test, HSV2 PCR test, Parvovirus B19 PCR test, P. Jirovecii PCR test, JCV PCR test, Adenovirus PCR test, and Aspergillus Spp PCR test
In 2024, CMV PCR test segment is expected to dominate the Global PCR Based Transplant Diagnostics Market
In 2024, CMV PCR test segment is expected to dominate the market with a market share of 45.32% because of the rising demand for organ transplantation.
- On the basis of transplant type, the global PCR based transplant diagnostics market is segmented into kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, and other transplantations
In 2024, kidney transplantation segment is expected to dominate the Global PCR Based Transplant Diagnostics Market
In 2024, kidney transplantation segment is expected to dominate the market with a market share of 65.28% due to the rising prevalence of kidney failure across the globe.
- On the basis of application, the global PCR based transplant diagnostics market is segmented into diagnostic applications, and research applications. In 2024, diagnostic application segment is expected to dominate the market with a market share of 96.44%
- On the basis of end user, the global PCR based transplant diagnostics market is segmented into hospitals and transplant centers, commercial service providers, and research laboratories and academic institutes. In 2024, hospitals and transplant centers segment is expected to dominate the market with a market share of 78.38%
Major Players
Data Bridge Market Research analyses Quest Diagnostics Incorporated. (U.S.), Laboratory Corporation of America Holdings (U.S.). EUROFINS VIRACOR (U.S.), Sonic Healthcare Limited (U.S.), and Dr Lal PathLabs (India) as the major players in the global PCR based transplant diagnostics market.
Market Development
- In January 2024, Laboratory Corporation of America Holdings launched a new test for preeclampsia in pregnant women which represents a significant advancement in maternal healthcare. This advanced diagnostic tools, healthcare providers can identify women at higher risk of severe preeclampsia earlier in their pregnancies. This allows the company for more vigilant monitoring and proactive medical intervention, potentially reducing the risk of complications and improving maternal and fetal outcomes
- In September 2023, Sonic Healthcare's acquired Healius Ltd., to provide development in the Australian healthcare landscape. This acquisition further solidifies Sonic's position as a global leader in pathology, strengthening its competitive edge against other international players. It signifies the company's commitment to expansion and consolidation within the industry, potentially paving the way for similar mergers in other regions
- In October 2023, Sonic Healthcare's invested in PaigeAI, an AI-powered pathology company, underscores their commitment to harnessing cutting-edge technology for improved diagnostic accuracy and efficiency in the field of pathology. This move holds significant implications for the future of medical diagnostics. This precision approach can lead to more effective treatments and potentially reduce the risk of side effects from unnecessary medications
- In August 2020, Eurofins Viracor collaborated with the Northwestern University Comprehensive Transplant Center, a leader in solid organ transplantation medicine in North America, through high-impact research and its clinical training programs. This research collaboration has further verified the novel test obtained through Eurofins’ recent acquisition of Transplant Genomics Inc. (“TGI”) and its blood gene expression test, TruGraf. TruGraf can rule out “silent” subclinical kidney rejection in kidney transplant patients with stable kidney function. TGI has recently received a draft Local Coverage Determination (LCD) decision from the Centers for Medicare & Medicaid Services (CMS) via Palmetto GBA’s Molecular Diagnostic Services (MolDX) Program. This has helped the company to validate its research
- In June 2020, Transplant Genomics, Inc. and Eurofins Viracor announced the development of the Eurofins Transplant Medical and Scientific Advisory Board, engaging diverse expertise and understanding in transplantation and technology development to improve the clinical value of diagnostics throughout the transplant community. Board associates are focusing on improvement and product development, utilizing their unique perspectives to help TGI and Viracor expand to serve the unmet needs in transplantation and guide future products. This has helped the company to expand its product portfolio
Regional Analysis
Geographically, the countries covered in the global PCR based transplant diagnostics market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to dominate the Global PCR Based Transplant Diagnostics Market
North America is expected to dominate the market owing to the higher level of investments by manufacturers and increasing application of PCR (Polymerase Chain Reaction) based transplant diagnostics for various diseases.
Asia-Pacific is expected to be the fastest-growing region in the Global PCR Based Transplant Diagnostics Market
Asia-Pacific is expected to grow during the forecast period due to the presence of major market players and rapid development in pharmaceutical and biotechnological industries in this region.
For more detailed information about the Global PCR Based Transplant Diagnostics Market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-pcr-based-transplant-diagnostics-market
